Filing Flows › Sanara MedTech (SMTI) › Stock forecast & fair value
Sanara MedTech (SMTI) stock forecast and fair value
Sanara MedTech (SMTI) trades at $35.07. The analysts' price target is $35.00 (-0.2%). Across 22 valuation methods the middle fair value is $41.01 (+17%); the DCF says $10.08.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | −$12.48 | $12.21 | $71.65 | -65% |
| DCF — Monte Carlo 10th–90th percentile | −$11.50 | $10.08 | $31.45 | -71% |
| P/E vs peers | $123.66 | $140.77 | $241.90 | +301% |
| P/E vs peers, weighted | $128.59 | $176.24 | $257.81 | +403% |
| P/E vs peers, matched | $119.14 | $177.10 | $347.34 | +405% |
| EV/EBITDA vs peers | $12.33 | $14.62 | $16.83 | -58% |
| EV/EBITDA vs peers, weighted | $12.39 | $14.94 | $16.88 | -57% |
| EV/EBITDA vs peers, matched | $16.47 | $24.40 | $29.20 | -30% |
| EV/Sales vs peers | $32.92 | $43.67 | $75.14 | +25% |
| EV/Sales vs peers, weighted | $38.35 | $53.20 | $99.99 | +52% |
Sanara MedTech's latest quarter
Sanara MedTech, Q2 2026: revenue $28.1M (+9% year over year), operating margin 6.3%, net loss $453K, operating cash flow $2.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for SMTI stock?
The analysts' 12-month target is $35.00, -0.2% from $35.07. The average rating is none.
What is Sanara MedTech's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $10.08 and $1,380.88, with a middle value of $41.01 against a price of $35.07. Each method's assumptions are on the page.
Does Sanara MedTech usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is SMTI stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.